ReviewClinical cancer research : an official journal of the American Association for Cancer Research2013
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.British journal of cancer · 2017Trial
- Evodiamine inhibits growth of vemurafenib drug-resistant melanoma via suppressing IRS4/PI3K/AKT signaling pathway.Journal of natural medicines · 2024Article
- MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Three-dimensional multicellular cell culture for anti-melanoma drug screening: focus on tumor microenvironment.Cytotechnology · 2021Article
- Converting melanoma-associated fibroblasts into a tumor-suppressive phenotype by increasing intracellular Notch1 pathway activity.PloS one · 2021Article
- HI-511 overcomes melanoma drug resistanceTheranostics · 2020Article
- Anorectal mucosal melanoma.Oncotarget · 2018Review
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.Cancer discovery · 2018Article
- Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.Oncogene · 2018Article
- BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma.Oncotarget · 2017Article
- Resistant mechanisms to BRAF inhibitors in melanoma.Annals of translational medicine · 2016Review
- Targeting inflammation in pancreatic cancer: Clinical translation.World journal of gastrointestinal oncology · 2016Review
- Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.British journal of cancer · 2016Article
- Pembrolizumab: A Review in Advanced Melanoma.Drugs · 2016Review
- Article
- Big opportunities for small molecules in immuno-oncology.Nature reviews. Drug discovery · 2015Review
- Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.Translational oncology · 2015Article
- A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.Molecular & cellular proteomics : MCP · 2015Article
- Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.Molecular oncology · 2015Review
- Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.Molecular cancer research : MCR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In three years, four drugs have gained regulatory approval for the treatment of metastatic and unresectable melanoma, with at least seven other drugs having recently completed, currently in, or soon to be in phase III clinical testing. This amazing achievement has been made following a remarkable increase of knowledge in molecular biology and immunology that led to the identification of high-valued therapeutic targets and the clinical development of agents that effectively engage and inhibit these targets. The discovery of either effective molecularly targeted therapies or immunotherapies would have led to dramatic improvements to the standard-of-care treatment of melanoma. However, through parallel efforts that have showcased the efficacy of small-molecule BRAF and MAP-ERK kinase (MEK) inhibitors, as well as the immune checkpoint inhibitors, namely ipilimumab and the anti-PD1/PDL1 antibodies (lambrolizumab, nivolumab, MPDL3280), an opportunity exists to transform the treatment of melanoma specifically and cancer generally by exploring rational combinations of molecularly targeted therapies, immunotherapies, and molecular targeted therapies with immunotherapies. This overview presents the historical context to this therapeutic revolution, reviews the benefits and limitations of current therapies, and provides a look ahead at where the field is headed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.